Exai Bio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3343 Thomas Dr, Palo Alto, California, 9...Phone Number
(650) 262-4516Website
exai.bioRevenue
$6.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Exai Bio
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The companys proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.Explore more
Exai Bio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exai Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Exai Bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Exai Bio
Click to see if Exai Bio had a recent Job posting/layoffs
Earning: See what the market has to say on Exai Bio recently announced quarterly report
Check if Exai Bio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Exai Bio has new funding data
Product Launch: Get notified when Exai Bio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Exai Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Exai Bio as Masked Content
Find 2 more new buyers
Compare Similar Companies to Exai Bio
Compare insights from companies similar to Exai Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Exai Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Exai Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Exai Bio.
Exai Bio financials insights
Gather financial insights about Exai Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$67.5M
Exai Bio Tech Stack
A closer look at the technologies used by Exai Bio
Most Recent Scoops
Funding
Project
Spending/Investment, Funding
Event
Product Marketing, Events, Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology
Event
Product Marketing, Events, Software, Field /Outside Sales, Field Marketing, Healthcare Operations, Healthcare Technology
New Hire
Executive Move
Executive Moves, New Hire
Event
Events
Exai Bio News & Media
Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform
PALO ALTO, Calif.--(BUSINESS WIRE)--Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its generative AI model in Nature Communications. The paper entitled “Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer” demonstrates that Exai’s generative AI model surpasses commonly used machine learning methods in overall lung cancer detection performance. ExaiExai Bio Appoints Dave Daly as Chief Executive Officer
PALO ALTO, Calif.--(BUSINESS WIRE)--Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced the appointment of Dave Daly as Chief Executive Officer. With more than 30 years of cancer diagnostics and executive leadership experience, including at Thrive Earlier Detection (acquired by Exact Science ‘EXAS’) and Foundation Medicine (acquired by Roche), Daly is ideally positioned to spearhead Exai’s accelerated product development and partnering strategy. ExExai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early Stage Breast Cancer with High Accuracy, Overcoming Many Limitations of DNA-based Approaches
PALO ALTO, Calif.--(BUSINESS WIRE)--Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes, including ductal carcinoma in situ (DCIS), using a standard blood sample. In a new early detection study building upon prior data, stage I breast cancer sensitivity was 87% and tumor size T1a-b (10 mm or smaller) sensitivity was 81%, both at 90% specificity.Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Exai Bio today announced non-small cell lung cancer (NSCLC) data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy. The study of nearly 900 subjects demonstrated stage I sensitivity was 95% at 90% specificity. The use of Exai’s proprietary generative AI technology, derived from large independent datasets of tumor and blood samples, enhanced both sensitivity and specificity bey
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Exai Bio
Sign Up For FreeTo access detailed company insights
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The companys proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enab... Read More
